Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    SLC2A2
Show Display Options
Rank Status Study
1 Not yet recruiting Real World Experience of Dapaglifozin in Type 2 Diabetes
Condition: Type2 Diabetes
Intervention:
2 Enrolling by invitation Pharmacogenetics of SGLT2 Inhibitors
Conditions: Diabetes Mellitus;   Gout;   Hyperuricemia
Intervention: Drug: Canagliflozin
3 Not yet recruiting Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Conditions: Type2 Diabetes;   Cardiovascular Diseases
Interventions: Drug: Dapagliflozin;   Drug: Glimepiride
4 Completed A First-in-Human Study of JNJ-28431754 in Healthy Male Volunteers
Condition: Healthy
Interventions: Drug: JNJ-28431754/ Placebo;   Drug: JNJ-28431754
5 Completed
Has Results
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Conditions: Diabetes Mellitus, Type 2;   Renal Insufficiency
Interventions: Drug: Canagliflozin;   Drug: Placebo
6 Completed
Has Results
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
Conditions: Diabetes Mellitus, Type 2;   Hypertension
Interventions: Drug: Canagliflozin;   Drug: Placebo

Study has passed its completion date and status has not been verified in more than two years.